Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial) [0.03%]
替戈拉肽与西格列汀治疗2型糖尿病的疗效和安全性：T-EMERGE 4试验
Richard M Bergenstal,Adriana Forti,Jean-Louis Chiasson et al.
Richard M Bergenstal et al.
Introduction: The efficacy and safety of taspoglutide, a long-acting human glucagon-like peptide-1 analog, were compared with sitagliptin or placebo, as adjunct to metformin, in patients with inadequately controlled type ...
Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin [0.03%]
接受二肽基肽酶-4抑制剂联合二甲双胍治疗的糖尿病患者出现药物性皮疹
Kaori Nakatani,Takeshi Kurose,Takanori Hyo et al.
Kaori Nakatani et al.
A generalized skin eruption with strong itching was induced by sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, in a patient almost 6 months after initiation of the drug. Physical examination revealed a spread of skin rash from ches...
Initial sulfonylurea use and subsequent insulin therapy in older subjects with type 2 diabetes mellitus [0.03%]
初服用磺脲类药物与2型糖尿病患者之后使用胰岛素的关系
Alex Z Fu,Ying Qiu,Michael J Davies et al.
Alex Z Fu et al.
Background: In type 2 diabetes mellitus (T2DM), progressive loss of beta cell function over time requires treatment intensification and eventually initiation of insulin for many patients. Relative to metformin, a greater ...
Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes [0.03%]
西格列汀和米格列醇联合治疗2型糖尿病的疗效观察
Miyako Kishimoto,Mitsuhiko Noda
Miyako Kishimoto
Introduction: To examine the efficacy of sitagliptin and miglitol when added to ongoing insulin treatment in a patient with type 2 diabetes who had undergone partial gastrectomy. ...
Linagliptin increases incretin levels, lowers glucagon, and improves glycemic control in type 2 diabetes mellitus [0.03%]
利格列汀通过增加胰高血糖素样肽-1的水平来降低胰高血糖素并改善2型糖尿病患者的血糖控制能力
Thomas Rauch,Ulrike Graefe-Mody,Carolyn F Deacon et al.
Thomas Rauch et al.
Introduction: Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to...
Clinical Outcomes After Insulin Initiation in Patients with Type 2 Diabetes: 24-Month Results from INSTIGATE [0.03%]
在2型糖尿病患者中启动胰岛素治疗后的临床结局：INSTIGATE研究24个月结果
Andreas Liebl,Steven Jones,Alberto Goday et al.
Andreas Liebl et al.
Introduction: To examine changes in insulin regimens and glycemic control during the 24 months after initiation of insulin in patients with type 2 diabetes mellitus. ...
Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin [0.03%]
二甲双胍使用时间等对维格列汀疗效影响的探讨
Anja Schweizer,Sylvie Dejager,James E Foley
Anja Schweizer
Introduction: The optimal stage for dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in the course of type 2 diabetes mellitus (T2DM) is still under discussion, with often a perception that treatment with these agents may...
Cost of Self-Monitoring of Blood Glucose in Canada among Patients on an Insulin Regimen for Diabetes [0.03%]
加拿大糖尿病患者自检血糖的成本分析
Jason Yeaw,Won Chan Lee,Michael Lyng Wolden et al.
Jason Yeaw et al.
Introduction: People with diabetes are at a higher risk of developing a variety of medical conditions relative to those without diabetes, resulting in increased healthcare costs. Self-monitoring of blood glucose (SMBG) is...
Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study [0.03%]
临床实践中启动利拉鲁肽和基础胰岛素治疗的2型糖尿病患者：CHOICE研究
Stephan Matthaei,Matthew Reaney,Chantal Mathieu et al.
Stephan Matthaei et al.
Introduction: Changes to Treatment and Outcomes in Patients with Type 2 Diabetes Initiating Injectable Therapy (CHOICE) is a European prospective, observational cohort study assessing time to, and factors associated with,...
Physician reasons for nonpharmacologic treatment of hyperglycemia in older patients newly diagnosed with type 2 diabetes mellitus [0.03%]
老年初诊2型糖尿病患者血糖非药物治疗的医师原因分析
Elizabeth Marrett,Qiaoyi Zhang,Claudia Kanitscheider et al.
Elizabeth Marrett et al.
Introduction: To identify reasons why primary care physicians (PCPs) do not treat older patients newly diagnosed with type 2 diabetes mellitus (T2DM) with antihyperglycemic agents following diagnosis. ...